
Pathology Update 2025
Practice Updates and Review of Diagnostic Pitfalls in Breast Pathology.
November 6 - 7, 2025 / Digital Conference
Learn about emergent developments and applications that are transforming the field of pathology.
Local and international experts will synthesize updates spanning all organ systems and sub-specialties of pathology. Large group learning activities and case-based discussions will share innovations spanning anatomical pathology and molecular pathology.
This year’s conference will revolve around the theme of Breast Pathology. Through expert-led sessions, we will explore the full spectrum of breast lesions – from benign, in-situ and malignant lesions in surgical and cytologic specimens — and address common diagnostic challenges with practical, evidence-based solutions. We will also review updates to breast cancer biomarker testing.
Join us as we delve into the latest updates that are shaping the future of breast cancer diagnostics and patient care.
The conference will review updates to breast pathology including cancer biomarker and DCIS reporting. In addition, diagnostic pitfalls in challenging areas of breast pathology will also be covered including breast fine needle aspirates, core biospies, spindle cell lesions and fibroepithelial lesions.
Conference Highlights
-
Keynote presentation from Dr. Ashley Cimino-Mathews (Johns Hopkins University School of Medicine)
-
11 plenary sessions sharing the latest evidence in diagnostic pathology
Target Audience
Pathologists working in all sub-specialties, pathologists' assistants, and pathology residents and fellows.
Learning Objectives
The two-day digital conference will enable attendees to:
- Describe the diagnostic criteria for the diagnosis of a wide variety of benign, in-situ and malignant breast lesions in surgical pathology and cytologic specimens.
- Identify diagnostic pitfalls and apply relevant ancillary investigation (immunohistochemistry, molecular) to resolve differential diagnoses in breast pathology.
- Discuss the updates to breast cancer biomarker testing.